Ордисс Н

Quick links

Choose a section

Quick links to important sections

Advertisements

Ордисс Н

Selected form

Advertisements
Advertisements

Treatment option:

Advertisements

Overview of Ордисс Н

Что такое Ордисс Н?

Свойство (Property) Описание (Description)
Активные ингредиенты (Active ingredients) Кандесартан (Candesartan), Гидрохлоротиазид (Hydrochlorothiazide)
Форма (Form) Таблетка (Tablet)
Фармакологический класс (Pharmacological class) Блокатор рецепторов ангиотензина II (АРБ) в комбинации с тиазидным диуретиком (Angiotensin II Receptor Blocker (ARB) combined with a Thiazide Diuretic)
Общее назначение (Common use) Управление артериальной гипертензией (Management of arterial hypertension)
Происхождение (Origin) Синтетическое (Synthetic)

Ордисс Н: Определение и Фармакологическая Классификация

Ордисс Н is a prescription-only, fixed-dose combination product for oral administration, officially classified as an Antihypertensive Agent. The medicine is a tablet containing two primary active substances: Candesartan and Hydrochlorothiazide. Its dual formulation represents a clinically recognized strategy for managing high blood pressure, often used when therapy with a single agent proves insufficient. The medication is defined by its dual pharmacological status: it is an Angiotensin II Receptor Blocker (ARB) combined with a Thiazide Diuretic.

Роли Компонентов: Блокатор Рецепторов Ангиотензина II и Тиазидный Диуретик

Candesartan is an ARB; it is provided as the prodrug Candesartan Cilexetil, which the body converts into the active drug upon absorption. Hydrochlorothiazide is a diuretic that facilitates fluid balance. Pharmacological studies consistently support the efficacy of combining these two agent classes for achieving superior blood pressure reduction. This requires the two synthetic substances to be physically housed within a single tablet matrix.

Общее Назначение Двухкомпонентной Терапии

The overall purpose of Ордисс Н is the comprehensive management of essential hypertension (high blood pressure). The strategic pairing of a substance that acts on the vascular system (Candesartan) and a substance that aids fluid regulation (Hydrochlorothiazide) is a well-established medical method for achieving optimal control of arterial pressure. This dual-component approach is typically reserved for adults requiring robust, sustained antihypertensive action.

Regulatory References

  1. NIH StatPearls on ARB and HCTZ Combination Drugs
Advertisements

What side effects are possible with Ордисс Н?

Possible Side Effects and Safety Information

This section describes the officially documented adverse reactions and safety characteristics for the Candesartan/Hydrochlorothiazide combination, as classified by government regulatory authorities.

Adverse Reactions by Frequency and System

Side effects are categorized based on their reported frequency in regulatory documentation:

  • Common Reactions (ge 1/100 to < 1/10): Typically include dizziness, headache, nausea, and symptoms categorized as Upper Respiratory Tract Infection. Metabolic effects such as hyperuricemia (elevated uric acid) are also classified as common.
  • Uncommon to Very Rare Reactions: Less frequent effects include vomiting and tachycardia. The Very Rare category contains serious events, such as Acute Respiratory Distress Syndrome (ARDS), reported in association with the Hydrochlorothiazide component.

The adverse reactions are grouped into System-Organ Classes (SOC), including Nervous System Disorders, Vascular Disorders (e.g., hypotension), Metabolism and Nutrition Disorders (e.g., electrolyte imbalance), and Eye Disorders (e.g., acute transient myopia, glaucoma).

Serious Safety Considerations and Constraints

Regulatory documents highlight several serious safety concerns and usage constraints:

  1. Fetal Toxicity: The medication is strictly contraindicated during the second and third trimesters of pregnancy due to the risk of injury and death to the developing fetus.
  2. Long-Term Exposure Risk: Increased, dose-dependent risk of Non-Melanoma Skin Cancer (Basal Cell Carcinoma and Squamous Cell Carcinoma) is associated with long-term cumulative exposure to Hydrochlorothiazide.
  3. Contraindications: Use is forbidden in individuals with severe renal impairment (creatinine clearance < 30 mL/min/1.73 m^2), severe hepatic impairment, anuria, and those with refractory hypokalemia or known hypersensitivity to sulfonamide-derived drugs.
Advertisements

Overdose and Emergency Response

Overdose and When to Seek Help: Official Regulatory Information

The official overdose profile for Ордисс Н (Candesartan/Hydrochlorothiazide) is defined by the exaggerated effects of its two components: profound blood pressure lowering and severe fluid loss.


Documented Overdose Manifestations

Feature Official Regulatory Statement
Cardiovascular/Hemodynamic The most likely presentations are severe hypotension (low blood pressure) and associated symptoms such as dizziness or syncope (fainting). Changes in heart rhythm, including tachycardia or, less frequently, bradycardia, may also occur.
Metabolic/Fluid Balance Overdose can lead to significant fluid loss and critical electrolyte imbalance, most notably hypokalemia (low potassium) and hyponatremia (low sodium), potentially resulting in severe volume depletion.
Severe Outcomes Profound hypotension may progress to life-threatening conditions, including shock and acute renal impairment.

Required Emergency Actions and Management

Individuals who suspect an overdose must seek immediate medical attention or contact emergency services at once.

Regulatory labeling specifies that no specific antidote is known for this combination drug. Management is strictly symptomatic and supportive treatment.

Required supportive measures include close hospital monitoring of vital signs, especially blood pressure, and laboratory monitoring to correct dehydration and fluid and electrolyte imbalance.

Advertisements

Therapeutic Uses of Ордисс Н

What Ордисс Н Treats: Main Uses and Benefits

Ордисс Н is commonly used for the chronic, supportive management of essential hypertension (high blood pressure) in adults. It is generally used across conditions where supportive blood pressure management is required. The medication is relevant for established essential hypertension and managing the condition in patients whose blood pressure is not optimally controlled by a single antihypertensive agent alone.

This combination is applied across domains where additional support is needed for sustained blood pressure management. It contributes to improved day-to-day comfort by helping address the symptoms related to heightened physiological activity. The core therapeutic benefit is to provide support that contributes to easing the overall symptom load of chronic high blood pressure. By supporting consistent pressure management, this treatment may assist in managing the risk of major cardiovascular events, and supports general well-being during symptomatic phases.

“This approach is relevant when symptoms that create noticeable physiological strain require comprehensive, sustained management over time.”


Quick Fact: Relief for Hypertension The medication assists with maintaining functional stability by helping manage the heightened risk of serious cardiovascular events that can arise from uncontrolled hypertension.

Advertisements

Eligibility and Restrictions for Use

Ordis H is a combination medication containing Fosinopril (an ACE inhibitor) and Hydrochlorothiazide (a thiazide diuretic), used to treat high blood pressure, typically after initial therapy with a single agent has proven insufficient.

Who Can Use Ordis H?

This medication is generally for adults with hypertension that requires combination therapy. Older adults may use it, but they may need careful dose adjustment due to potential age-related changes in liver, kidney, or heart function. The medication is not recommended for use as initial therapy for high blood pressure.


Who Cannot Use Ordis H? (Contraindications)

Ordis H should not be used by individuals with certain medical conditions or circumstances. Consult your healthcare provider if any of the following apply to you:

  • Allergy or Hypersensitivity: Known allergy to fosinopril or any other ACE inhibitor, hydrochlorothiazide or other thiazides, or sulfonamide-derived drugs (due to potential cross-sensitivity with hydrochlorothiazide).
  • Angioedema: A history of angioedema (severe swelling of the face, lips, tongue, or throat) related to previous ACE inhibitor treatment.
  • Pregnancy: Use during the second or third trimester of pregnancy can cause injury or death to the developing fetus; discontinue immediately if pregnancy is detected.
  • Anuria: Inability to produce urine.
  • Concomitant Use: Taking Aliskiren if you have diabetes or kidney impairment; or taking Sacubitril/Valsartan.
Advertisements

What should I know about interactions with other medicines?

Interactions with other medicines and products: Official Regulatory Information

The regulatory interaction profile for Ордисс Н is structured around the recognized risks associated with its Angiotensin II Receptor Blocker (Candesartan) and Thiazide Diuretic (Hydrochlorothiazide, HCTZ) components.

Interaction Classification Official Constraint
Contraindicated Combinations Co-administration with Lithium is restricted due to the potential for elevated plasma concentrations and increased risk of toxicity. Use with Aliskiren is strictly contraindicated in patients with diabetes or moderate-to-severe renal impairment, reflecting the severe risk of dual blockade of the Renin-Angiotensin-Aldosterone System (RAAS).
Pharmacodynamic Effects Concomitant use with Potassium-sparing diuretics or Potassium supplements increases the documented risk of hyperkalemia. Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) may reduce the blood pressure-lowering effect and can increase the risk of worsening renal function.

Timing and Absorption Rules: To prevent reduced HCTZ exposure, the label specifies a mandatory timing rule: the medicine must be administered separated by at least four to six hours from co-administered resins (Cholestyramine or Colestipol). Substances that cause hypotension, such as alcohol, barbiturates, or narcotics, may potentiate orthostatic hypotension due to the additive effects of the diuretic component. Regulatory documentation defines these constraints to strictly govern co-administration.

Advertisements

Mechanism of Action

Action on Vascular Tone and Resistance Pathways

Ордисс Н acts on the body’s hormonal system that controls blood vessel tightening, the Renin-Angiotensin-Aldosterone System (RAAS). The Candesartan component is a selective antagonist that blocks the Angiotensin II Type 1 receptor (AT1) on vessel walls, suppressing the signaling that promotes muscle contraction. This action initiates a molecular cascade that leads to systemic vasodilation (widening of the vessels) and a decrease in peripheral resistance.


Direct Interference with Renal Sodium and Volume Transport

The Hydrochlorothiazide component engages a complementary mechanism by acting directly on the kidneys. It functions as an inhibitor of the Sodium Chloride Symporter (Na^+/Cl^- cotransporter) in the distal tubules, which prevents the reabsorption of salt and water back into the blood. This inhibition results in increased natriuresis and diuresis (excretion of salt and water), causing a reduction in plasma volume.


Complementary Mechanism and Compensation Blockade

The two mechanisms interact in a complementary manner. The Candesartan component prevents the cardiovascular system from initiating compensatory feedback (RAAS activation) that occurs in response to the volume loss induced by the diuretic. By simultaneously modulating vascular tone and fluid volume, the dual mechanism addresses both the fluid volume and the vascular tone components of pressure regulation.

Advertisements

Dosage and Administration Information

How to Use Ордисс Н: Administration Guidelines

Ордисс Н is a fixed-dose combination product containing Candesartan and Hydrochlorothiazide, and its usage is defined by clinical context. The medication is an oral tablet administered once daily.


Administration and Dosage Structure

The combination product is not intended for initiating therapy for essential hypertension. Its use is reserved for adult patients whose blood pressure is not adequately controlled by the monotherapy of Candesartan or Hydrochlorothiazide alone.

Instruction Description
Route & Method Administered orally. The tablet must be swallowed whole and should not be broken, crushed, or chewed.
Timing & Frequency Taken once daily, and may be administered with or without food.
Dose Limit The maximum recommended dose is the highest available strength, 32 mg Candesartan / 25 mg Hydrochlorothiazide, taken once daily.

Usage Constraints for Specific Populations

Prescribing information places constraints on the use of this combination based on specific patient conditions. Use is not recommended in patients with severe renal impairment (creatinine clearance < 30 mL/min/1.73 m^2). Furthermore, the fixed combination is not recommended for initiation in cases of moderate hepatic impairment, as the appropriate lower starting dose of Candesartan cannot be achieved with the combination tablet. No initial dose adjustment is typically necessary for older adults. The full antihypertensive effect is generally achieved within four weeks of initiating treatment.

Advertisements

Recent Clinical Evidence

Ордисс Н: Recent Clinical Evidence

Research on the compound associated with Ordiss N has focused on investigating its activity in laboratory models and its influence on chronic pain in clinical trials. The evidence summary below is based on published studies.


Research on Compound Properties

Studies were conducted to investigate the compound's potential influence in laboratory models. This research primarily focused on examining how the compound interacts with specific biological pathways associated with immune responses, evaluating whether it could modulate the activity of certain inflammatory markers in cell models.

  • Findings from in vitro (non-human cell) settings suggested that the compound might influence the release of pro-inflammatory cytokines.
  • Preliminary research also examined T-cell activation markers, with some studies suggesting a change in proliferation markers.

Clinical Efficacy Trials

Research has been conducted to investigate chronic pain severity in participants receiving the drug in randomized controlled trials (RCTs).

Phase 3 Randomized Controlled Trials

In major Phase 3 trials, the primary goal was to evaluate the change in patient-reported pain scores over a 12-week period. For example, one RCT examined whether a daily dose was associated with a change in pain intensity.

Primary Outcome Finding Study Type
Pain Intensity Score A 40% average reduction in pain scores was observed in the treated group compared to the placebo group. RCT (12 Weeks)
Frequency of Flare-ups One study noted a difference in the number of flare-ups reported by the treated group compared to the control group over six months. Long-term Follow-up

Combination Therapy

The effect of combining the treatment with physical therapy was also evaluated in a small pilot study. Findings from this trial were mixed regarding whether the combination provided a statistically significant difference in long-term functional improvement compared to the drug alone.


Safety Profile

Safety data from clinical trials described the profile of adverse events observed in adults. Adverse events reported in the trials were typically described by researchers as non-serious. The most commonly reported adverse events included mild headache and temporary digestive upset.

Research on the compound's influence in specific populations, such as those with existing heart conditions or during pregnancy, continues to be evaluated.

Key Studies & References

  1. Opioids and Chronic Pain: An Analytic Review of the Clinical Evidence (Systematic Review covering Efficacy and Safety)
  2. Systematic Review on Opioid Treatments for Chronic Pain: Surveillance Report 3 (RCT and Harm Data)
Advertisements

Frequently Asked Questions (FAQ)

Common questions about Ордисс Н (FAQ)

Q: What are the general signs that indicate Ордисс Н is working as intended?

The overall purpose of this medication, according to regulatory documents, is the reduction and control of elevated arterial blood pressure. Because high blood pressure often has no noticeable symptoms, the medication’s effectiveness is generally assessed by measuring blood pressure over time.


Q: Are there any general expectations for how a person might feel when first starting Ордисс Н?

Official product information indicates that a person may experience common adverse reactions when first starting the medication. These can include feelings like temporary dizziness or headache. Such effects are generally reported to occur during the initial period of treatment as the body adjusts.


Q: What types of dietary supplements or herbal products are known to potentially interact with Ордисс Н?

Official warnings state that products containing Potassium, such as some supplements or salt substitutes, may increase the documented risk of having too much potassium in the blood (hyperkalemia). General herbal supplements are not specifically listed in regulatory documents with known interactions.


Q: Is there an interaction risk with common medications for high blood pressure or cholesterol?

Regulatory documents do not list specific interactions with common cholesterol-lowering medications (statins). However, combining the medication with other blood pressure-lowering agents, such as Aliskiren, is strictly contraindicated (forbidden) for patients with diabetes or kidney impairment.


Q: How does the body typically process and eliminate Ордисс Н?

Official pharmacokinetic data explains how the body handles the medication. The Candesartan component is rapidly converted into its active form after it is taken. Both active substances are then primarily processed and eliminated from the body through the urine and bile.


Q: What is the typical duration of treatment or course of therapy with Ордисс Н?

According to official guidelines, this medication is generally intended for the long-term, sustained management of essential hypertension (high blood pressure). Achieving long-term control of blood pressure generally involves ongoing use of the medication.


Q: What happens in the body if the medication is stopped abruptly?

Discontinuation of the medication will result in the loss of its blood pressure-lowering effect. This means the underlying high blood pressure will return. Regulatory information does not contain specific warnings regarding acute withdrawal or rebound hypertension associated with stopping the drug.


Q: How is an allergic reaction to Ордисс Н officially described, and what are the signs?

The official label highlights the risk of Angioedema, which is a severe swelling of the face, lips, throat, or tongue, associated with the class of medicine. Less severe hypersensitivity reactions may also occur, which can manifest as a rash or itching.


Q: Are there warnings about activities like driving or operating machinery while taking Ордисс Н?

Regulatory warnings state that the medication may cause side effects such as dizziness or tiredness. These effects are listed as potentially impacting the ability to drive or operate machinery. This is noted as a particular concern when first starting treatment or when the dose is increased.


Q: Does Ордисс Н carry a regulatory warning about potential changes in mental state or mood?

Official adverse reaction documents list anxiety and depression under the System-Organ Class for Psychiatric Disorders. These events are generally categorized as uncommon or rare based on the data collected from clinical trials.


Q: What information is provided regarding the signs of an overdose related to Ордисс Н?

Official information regarding overdose states that signs are primarily associated with excessive hypotension, meaning severely low blood pressure. Other potential symptoms include electrolyte disturbances such as hyperkalemia (high potassium) and hyponatremia (low sodium).


Q: Is Ордисс Н approved for use in specific pediatric age groups?

According to the regulatory agency's Pediatric Use section, the medication is not approved for use in patients under 18 years of age. The official use is limited to the adult population.


Q: Is there a stated exclusion for patients with uncontrolled heart conditions?

The official label lists specific limitations regarding use in patients with severe congestive heart failure (CHF) or severe valve narrowing (aortic or mitral stenosis). This caution is due to the potential for a sudden drop in blood pressure, which could worsen these pre-existing cardiac conditions.


Q: Is it true that natural products cannot interact with Ордисс Н?

The statement that natural products cannot interact is inconsistent with the official regulatory information. The product label explicitly lists a potential interaction with Potassium supplements, which are considered natural product derivatives. This risk is noted because of the potential for increased potassium levels in the blood.


Advertisements

How should Ордисс Н be stored and disposed of?

Official Storage and Disposal Requirements

The storage and disposal of Candesartan/Hydrochlorothiazide tablets (Ордисс Н) must strictly adhere to regulatory requirements to maintain product stability and ensure public safety.

Requirement Area Official Instructions
Temperature & Protection Store at controlled room temperature (typically 20 C to 25 C). Must be protected from heat, moisture, and direct light. Do not freeze.
Container & Integrity Keep the medicine in the original container and ensure it is tightly closed. Tablets should remain in the blister until use.
Child Safety Mandatory instruction to keep out of the reach and sight of children.
Disposal Protocol Do not dispose of via wastewater or household waste. Patients should consult a healthcare professional for guidance on proper disposal of unused or expired medicine according to local regulations.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Ордисс Н found in:

A-Z Index: